Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Press Releases

No. 06 | 02. February 2023

Significant improvement for clinical cancer research in Germany

© NCT/Marius Stark

The National Center for Tumor Diseases (NCT) is a long-term cooperation between the German Cancer Research Center (DKFZ), university medical centers, and other outstanding research partners at various sites in Germany. On February 2, 2023, the German Federal Ministry of Education and Research (BMBF) has confirmed the NCT expansion with four new sites: Berlin, SouthWest (Tübingen/Stuttgart-Ulm), WERA (Würzburg with partners Erlangen, Regensburg, and Augsburg), and West (Essen/Cologne). With the existing sites in Heidelberg and Dresden, a total of six NCT sites are now cooperating with the DKFZ with the aim of sustainably advancing state-of-the-art clinical cancer research in Germany and thereby improving the treatment outcomes and quality of life of cancer patients.

read more

No. 04 | 24. January 2023 | by Koh

What keeps the immune defense in brain tumors functional

Immune cells attacking cancer cells
© Adobe Stock

Cancer immunotherapies often fail because the immune cells are paralysed by immunosuppressive conditions in the tumor. Scientists from Heidelberg, Mannheim and Tel Aviv have now shown on tissue samples from patients as well as on tumor models in mice that the functionality of the immune defence depends decisively on certain helper cells.

Joint press release of the German Cancer Research Center (DKFZ), Mannheim University Medical Center (UMM), Heidelberg University Hospital (UKHD) and the German Consortium for Translational Cancer Research (DKTK)

read more

No. 03c2 | 23. January 2023 | by Koh

Brain stem cells are contolled by interferon during the entire lifetime

Interferone controls brain stem cells during the entire lifetime
© Nevit Dilmen/Wikipedia

Interferons represent the first line of defence against viral infections and are at the same time an important cause of the age-related loss of function of brain stem cells. Scientists from the German Cancer Research Center (DKFZ) and the University of Heidelberg have now shown in mice that interferon regulates the activity and self-renewal of brain stem cells throughout life: In young brains, it increases, but in the less active ageing brain, it reduces the production of nerve progenitor cells. In older age, a blockade of interferon signals could possibly slow down this process and counteract the age-related decline in brain function.

read more

No. 03c | 20. January 2023 | by Koh

Czech Inventor Award for Martina Benešová-Schäfer

Martina Benešová-Schäfer
© Jung/DKFZ

With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague. She received the Czech Inventor Award for the development of agents for the diagnosis and therapy of prostate cancer.

read more

No. 02 | 17. January 2023 | by Koh

Blood stem cells: not in charge in an emergency!

It is not the blood stem cells in the bone marrow, but multipotent progenit...
© Adobe Stock

After infections or blood loss, the body must compensate for the loss of blood cells as quickly as possible. This has long been considered the task of the hematopoietic stem cells in the bone marrow. But scientists at the German Cancer Research Center (DKFZ) have now discovered in mice that a certain population of progenitor cells takes over this task: This accelerates the regeneration of the blood cells and possibly protects the stem cells from exhaustion.

read more

No. 74 | 20. December 2022 | by Koh

Enzyme inhibition promotes bone formation and curbs the development of bone metastases

Breast carcinoma with osteolytic metastases
© Hellerhoff/Wikipedia

In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts. An agent that inhibits the activity of this enzyme reduced cancer-related bone loss and the number of bone metastases in multiple myeloma and in lung and breast cancer models in mice.

read more

No. 72c | 15. December 2022

How brain tumors keep the beat - and why that makes them so dangerous

© Uniklinikum Heidelberg

Scientists from Heidelberg University Hospital and the German Cancer Research Center describe tumor cells with pacemaker function in highly aggressive glioblastomas in "Nature" / pacemaker tumor cells promote growth and resistance of the brain tumor network / Research work within the framework of the UNITE research consortium under the leadership of the Neurological University Hospital Heidelberg

read more

No. 72 | 14. December 2022 | by Koh

New drug for metastatic prostate cancer now also approved in Europe

Light microscopic image of a prostate adenocarcinoma
© Wikipedia/KGH

On December 13, 2022, the European Commission granted approval to a drug against metastatic prostate cancer whose active ingredient was developed under the leadership of the German Cancer Research Center (DKFZ) in collaboration with Heidelberg University Hospital and Heidelberg University. The drug can significantly improve the survival chances of patients. The patented invention on which the drug is based is an outstanding example of the transfer of excellent research results into clinical application, says DKFZ board member Michael Baumann.

read more

No. 71 | 09. December 2022 | by Koh

Epigenetic emergency switch improves defense against infections

Blood stem cells and progentor cells in the bone marrow can switch from nor...
© Adobe Stock

During infections, the hematopoietic system switches from normal to emergency mode. This improves the defense against the pathogens. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now found an epigenetic switch in blood stem cells and progenitor cells of mice that can trigger the switch from one mode to the other.

read more

No. 66b | 23. November 2022

How blood cancer cells renew themselves

© Wikimedia Commons

Scientists at Heidelberg University Hospital, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and HI-STEM gGmbH* have discovered a new mechanism for the self-renewal of leukemia stem cells. The study results help to better understand the aggressive course of acute myeloid leukemia.

read more

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS